Randal W. Scott is Director at BridgeBio Pharma, Inc. (BBIO). They have made 4 open-market trades across 2 companies since 2021, most recently 2026-05-15.
3 open-market purchases totalling $6.2M since 2021, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BBIO | 11,589 | $769K |
| TLIS | 20,000 | $88K |
| NVTA | 161,222 | $14K |
| Total | $871K |
Shares reported on the most recent Form 4, priced at the 2026-05-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BBIO | SELL · 10b5-1 | 2026-05-15 | 2026-05-19 | $67.15 | $671K | -2.4% | -1.2% | +19.2% |
| BBIO | SELL | 2026-02-17 | 2026-02-18 | $75.46 | $755K | -10.7% | -6.6% | -10.0% |
| BBIO | SELL · 10b5-1 | 2025-11-17 | 2025-11-19 | $66.65 | $1.3M | +7.6% | +14.9% | +14.2% |
| BBIO | SELL · 10b5-1 | 2024-06-03 | 2024-06-05 | $30.32 | $76K | -2.1% | -7.4% | +3.3% |
| BBIO | SELL · 10b5-1 | 2024-03-01 | 2024-03-05 | $34.00 | $85K | -9.0% | -7.1% | -4.4% |
| BBIO | SELL · 10b5-1 | 2023-12-18 | 2023-12-20 | $40.00 | $80K | -1.7% | -4.8% | -26.1% |
| BBIO | SELL · 10b5-1 | 2023-12-01 | 2023-12-05 | $29.40 | $74K | +23.4% | +15.7% | +1.4% |
| BBIO | SELL · 10b5-1 | 2023-09-05 | 2023-09-07 | $30.00 | $75K | -2.3% | -11.1% | +12.5% |
| TLIS | BUY | 2021-05-14 | 2021-05-18 | $10.13 | $203K | -9.5% | -5.3% | -28.4% |
| TLIS | BUY | 2021-02-17 | 2021-02-19 | $16.00 | $5.0M | -34.3% | -38.7% | -54.8% |
| BBIO | BUY | 2021-02-17 | 2021-02-18 | $62.50 | $1.0M | +0.6% | +5.1% | -16.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.